Skip to content
Menu

RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.

Read at benzinga.com